Article

Overexpression of Dimethylarginine Dimethylaminohydrolase Protects Against Cerebral Vascular Effects of Hyperhomocysteinemia

Department of Internal Medicine, C32 GH, The University of Iowa, Iowa City, IA 52242, USA.
Circulation Research (Impact Factor: 11.09). 12/2009; 106(3):551-8. DOI: 10.1161/CIRCRESAHA.109.200360
Source: PubMed

ABSTRACT Hyperhomocysteinemia is a cardiovascular risk factor that is associated with elevation of the nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA).
Using mice transgenic for overexpression of the ADMA-hydrolyzing enzyme dimethylarginine dimethylaminohydrolase-1 (DDAH1), we tested the hypothesis that overexpression of DDAH1 protects from adverse structural and functional changes in cerebral arterioles in hyperhomocysteinemia.
Hyperhomocysteinemia was induced in DDAH1 transgenic (DDAH1 Tg) mice and wild-type littermates using a high methionine/low folate (HM/LF) diet. Plasma total homocysteine was elevated approximately 3-fold in both wild-type and DDAH1 Tg mice fed the HM/LF diet compared with the control diet (P<0.001). Plasma ADMA was approximately 40% lower in DDAH1 Tg mice compared with wild-type mice (P<0.001) irrespective of diet. Compared with the control diet, the HM/LF diet diminished endothelium-dependent dilation to 10 micromol/L acetylcholine in cerebral arterioles of both wild-type (12 + or - 2 versus 29 + or - 3%; P<0.001) and DDAH1 Tg (14 + or - 3 versus 28 + or - 2%; P<0.001) mice. Responses to 10 micromol/L papaverine, a direct smooth muscle dilator, were impaired with the HM/LF diet in wild-type mice (30 + or - 3 versus 45 + or - 5%; P<0.05) but not DDAH1 Tg mice (45 + or - 7 versus 48 + or - 6%). DDAH1 Tg mice also were protected from hypertrophy of cerebral arterioles (P<0.05) but not from accelerated carotid artery thrombosis induced by the HM/LF diet.
Overexpression of DDAH1 protects from hyperhomocysteinemia-induced alterations in cerebral arteriolar structure and vascular muscle function.

Download full-text

Full-text

Available from: Daryl J Murry, Jul 07, 2015
0 Followers
 · 
177 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nitric oxide (NO) is a structurally simple, highly versatile molecule that was originally discovered over 30 years ago as an endothelium-derived relaxing factor. In addition to its vasorelaxing effects, NO is now recognized a key determinant of vascular health, exerting antiplatelet, antithrombotic, and anti-inflammatory properties within the vasculature. This short-lived molecule exerts its inhibitory effect on platelets largely through cGMP-dependent mechanisms, resulting in a multitude of molecular effects by which platelet activation and aggregation are prevented. The biosynthesis of NO occurs via the catalytic activity of nitric oxide synthase (NOS), an oxido-reductase found in many cell types. Nitric oxide insufficiency can be attributed to limited substrate/cofactor availability as well as interactions with reactive oxygen species (ROS). Impaired NO bioavailability represents the central feature of endothelial dysfunction, a common abnormality found in many vascular diseases. In this review, we present an overview of NO synthesis and biochemistry, discuss the mechanisms of action of NO in regulating platelet and endothelial function, and review the effects of vascular disease states on NO bioavailability.
    Hematology Research and Reviews 08/2010; 2010(1):147-162. DOI:10.2147/JBM.S7000
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vascular dilatation is critically impaired in many diseases and is encountered by an upregulated endothelin receptor A (ETA) in the vasculature in association with a decline in nitric oxide bioavailability. Diabetic vasculopathy is characterized as a compromised vascular dilatation, implicated in many diabetic complications. It appears to be activated ETA and NADPH (nicotinamide adenine dinucleotide phosphate) oxidase in the vasculature. Glucose-lowering agents do not always blunt these changes, as these changes may be progressive leading to the end stage of renal disease. The vascular insults by hypertension, hyperglycemia and aging may share the changes with diabetic vascular beds. Endothelin receptor antagonist CPU0213 and ingredients from plant origins such as CPU86017, p-benzyl-tetra-hydro-berberine are effective in attenuating vascular abnormality by normalizing changes of biomarkers in the vascular wall. The early sign of subclinical atherosclerosis presented as an intima media thickness in the carotid may indicate endothelium dysfunction. The reduced ABI (ankle brachial index) has been taken to predict patients at risk for cardiovascular and cerebrovascular events, and an increased risk of mortality from all causes and cardiovascular disease. An application of agents which suppress the activated ET-NADPH oxidase in the vascular wall is beneficial to attenuate vascular abnormalities. It is worth testing the activity of these agents further for the potential in relieving abnormal vascular activity, reducing the risk of morbidity and mortality in patients at risk.
    Vascular Health and Risk Management 09/2010; 6:787-94. DOI:10.2147/VHRM.S6556
  • [Show abstract] [Hide abstract]
    ABSTRACT: • The endothelial nitric oxide synthase (eNOS) pathway is highly modulated by nutrition. • Dietary choices and interventions may modulate endothelial function. • The Mediterranean diet enhances endothelial vasodilator function and reduces major adverse cardiovascular events (MACE). • Increased dietary consumption of fish and other sources of omega-3 fatty acids improve NO activity, and also reduce MACE in those with cardiovascular disease. • A number of nutritional supplements may improve endothelial function by reducing oxidative stress, by restoring elements of the NOS pathway, or by ameliorating insulin resistance, hypertension, or hyperlipidemia; however, their long-term effects on MACE are unknown. • Some dietary supplements known to enhance the NOS pathway and improve endothelial vasodilator function in humans (Vitamin E, the B vitamins, and l-arginine) were ineffective at reducing MACE in large randomized clinical trials. • Thus, dietary interventions that improve endothelial vasodilator function in the short term might not necessarily have long-term benefit. KeywordsDiet-Nutrition-Mediterranean diet-Vitamins-Cardiovascular disease-Functional foods
    12/2010: pages 97-122;